This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-26. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Even during digestion, in general, one or two hours following a meal, insulin release from the pancreas is not continuous, but oscillates with a period of 3–6 minutes, changing from generating a blood insulin concentration more than about 800 p mol/l to less than 100 pmol/L (in rats). This is thought to avoid downregulation of insulin receptors in target cells, and to assist the liver in extracting insulin from the blood. This oscillation is important to consider when administering insulin-stimulating medication, since it is the oscillating blood concentration of insulin release, which should, ideally, be achieved, not a constant high concentration. This may be achieved by delivering insulin rhythmically to the portal vein, by light activated delivery, or by islet cell transplantation to the liver.
Beginning in the 1970s, the emphasis shifted to abstinence and the use of methadone; currently, only a small number of users in the UK are prescribed diamorphine. In 1994, Switzerland began a trial diamorphine maintenance program for users that had failed multiple withdrawal programs. The aim of this program was to maintain the health of the user by avoiding medical problems stemming from the illicit use of diamorphine. The first trial in 1994 involved 340 users, although enrollment was later expanded to 1000, based on the apparent success of the program. The trials proved diamorphine maintenance to be superior to other forms of treatment in improving the social and health situation for this group of patients. It has also been shown to save money, despite high treatment expenses, as it significantly reduces costs incurred by trials, incarceration, health interventions and delinquency. Patients appear twice daily at a treatment center, where they inject their dose of diamorphine under the supervision of medical staff. They are required to contribute about 450 Swiss francs per month to the treatment costs. A national referendum in November 2008 showed 68% of voters supported the plan, introducing diamorphine prescription into federal law. The previous trials were based on time-limited executive ordinances. The success of the Swiss trials led German, Dutch, and Canadian cities to try out their own diamorphine prescription programs.
== Habitat and ecology == Rhizopus oryzae can be found in various soils across the world. For example, it has been found in India, Pakistan, New Guinea, Taiwan, Central America, Peru, Argentina, Namibia, South Africa, Iraq, Somalia, Egypt, Libya, Tunisia, Israel, Turkey, Spain, Italy, Hungary, Czech Republic, Slovakia, Germany, Ukraine, British Isles, and the USA. The soils where R. oryzae has been isolated are varied ranging from grassland, cultivated soils under lupin, corn, wheat, groundnuts, other legumes, sugar canes, rice, citrus plantations, steppe type vegetation, alkaline soils, salt-marshes, farm manure soils, to sewage filled soils. The pH of the soils where the species has been isolated typically range from 6.3 to 7.2. Rhizopus oryzae is often identified as R. arrhizus when isolated from foods. It is found in rotting fruits and vegetables where it is often called R. stolonifer. Unlike the other species such as R. stolonifer, R. oryzae is common in tropical conditions. In East Asia, it is common in peanuts. For instance, there was 21% isolation from peanut kernels from Indonesia. It is present in maize, beans, sorghum, and cowpeas, pecans, hazelnuts, pistachios, wheat, barley, potatoes, sapodillas, and various other tropical foods. Maize meal on which isolates of R. oryzae had been grown was found to be toxic to ducklings and rats, causing growth depression.
=== Codeine === Codeine is a prodrug which is converted to morphine and acts on μ-opiate receptors. It is converted to morphine by metabolism of CYP2D6 enzymes. Individuals who have lower CYP2D6 activity may not metabolize codeine at all, and will not experience its analgesic effects. Conversely, individuals with rapid or ultra-rapid CYP2D6 activity may metabolize the drug too quickly and experience dose-related side effects such as sedation and fatal respiratory depression.
a 5-year surveillance study to determine if resistance emerges, with the final report due in December 2022 a study of the IV form in pregnant rats to determine distribution to the reproductive tract, due June 2018, with further studies required if there is significant distribution. Melinta merged with Cempra in August, 2017. Melinta has entered into commercialization and distribution agreements with both Menarini Therapeutics (March 2017) and Eurofarma Laboratórios (January 2015) for international commercialization of delafloxacin. The agreement with Menarini allows them to commercialize and distribute in 68 countries, including Europe, China, and South Korea among others. A similar agreement with Eurofarma allows for commercialization in Brazil.
Sources: en.wikipedia.org
=== Policy === Since the mid-1980s pharmaceutical companies have invested in medications for cancer or chronic disease that have greater potential to make money and have "de-emphasized or dropped development of antibiotics". On 20 January 2016 at the World Economic Forum, "80 pharmaceutical and diagnostic companies" called for "transformational commercial models" at an international level to spur research and development on antibiotics and on the use of diagnostic tests. A number of countries are considering or implementing delinked payment models for new antimicrobials whereby payment is based on value rather than volume of drug sales. This offers the opportunity to pay for valuable new drugs even if they are reserved for use in relatively rare drug resistant infections.
== Preventing human infection == A large proportion of reported cases of infection had a history of freshwater exposure, 58% from swimming or diving, 16% from bathing, 10% from water sports such as jet skiing, water skiing, and wakeboarding, and 9% from nasal irrigation. Methods of infection prevention, therefore, focus on precautions to be taken around water to prevent water from entering the nose, particularly during warmer weather. Wearing a nose clip when swimming may help prevent contaminated water from travelling up the nasal cavity. Keeping the head above water and not jumping or diving into warm freshwater may also prevent contaminated water from going up the nose. Swimmers should also avoid digging or stirring up sediment at the bottom of lakes, ponds, and rivers, as this is where amoebae are most likely to live. When irrigating sinuses or taking part in ritual cleansing of the nasal cavity, it is advised to use distilled water or tap water that has been boiled and then cooled.
t1/2 is the elimination half life of the compound. tmax is the time to peak plasma levels after oral administration of amoxapine. CSS is the steady state plasma concentration. protein binding is the extent of plasma protein binding. Vd is the volume of distribution of the compound.
== Pharmacokinetics == The main metabolites of Prajmaline are: 21-carboxyprajmaline and hydroxyprajmaline. Twenty percent of the drug is excreted in the urine unchanged. Daily therapeutic dose is 40–80 mg. Distribution half-life is 10 minutes. Plasma protein binding is 60%. Oral bioavailability is 80%. Elimination half-life is 6 hours. Volume of distribution is 4-5 L/kg.
==== 2004–2008 ==== In June 2004 and again in December 2005, the JINR–LLNL collaboration strengthened their claim for the discovery of element 113 by conducting chemical experiments on 268Db, the final decay product of 288115. This was valuable as none of the nuclides in this decay chain were previously known, so that their claim was not supported by any previous experimental data, and chemical experimentation would strengthen the case for their claim, since the chemistry of dubnium is known. 268Db was successfully identified by extracting the final decay products, measuring spontaneous fission (SF) activities and using chemical identification techniques to confirm that they behave like a group 5 element (dubnium is known to be in group 5). Both the half-life and decay mode were confirmed for the proposed 268Db which lends support to the assignment of the parent and daughter nuclei to elements 115 and 113 respectively. Further experiments at the JINR in 2005 confirmed the observed decay data. In November and December 2004, the Riken team studied the 205Tl + 70Zn reaction, aiming the zinc beam onto a thallium rather than a bismuth target, in an effort to directly produce 274Rg in a cross-bombardment as it is the immediate daughter of 278113. The reaction was unsuccessful, as the thallium target was physically weak compared to the more commonly used lead and bismuth targets, and it deteriorated significantly and became non-uniform in thickness. The reasons for this weakness are unknown, given that thallium has a higher melting point than bismuth.
Sources: en.wikipedia.org
I don't think there was anything else like it at the time. Before TGI Fridays, four single twenty-five-year-old girls were not going out on Friday nights, in public and with each other, to have a good time. They went to people's apartments for cocktail parties or they might go to a real restaurant for a date or for somebody's birthday, but they weren't going out with each other to a bar for a casual dinner and drinks because there was no such place for them to go. TGI Fridays was one of the first to use promotions such as ladies' night, and Stillman achieved his hopes of meeting women; "Have you seen the movie Cocktail? Tom Cruise played me!...Why do girls want to date the bartender? To this day, I'm not sure that I get it." He and the restaurant benefited from its location—according to Stillman, 480 stewardesses lived in the apartment building next door—and received publicity in national magazines. TGI Fridays became so popular that it had to install ropes to create an area for those waiting in line, also unusual at the time for a restaurant. A competitor, Maxwell's Plum, opened across the street, and others soon followed. With fellow Bucknell University graduate Ben Benson, Stillman opened other restaurants, including Tuesday's, Thursday's, Wednesday's, and Ice Cream Sunday's. Franchising of TGI Fridays began two years after the Manhattan location opened, in a since-closed location in Memphis, Tennessee's Overton Square district. In 1971, Daniel R. Scoggin acquired the rights to eight major Midwest cities. In 1972, he opened with the first of a new prototype in Dallas.
=== Disease association === Genetic variants and haplotypes (i.e., allotypes) of ERAP1 have been associated with a wide variety of inflammatory conditions, infectious diseases, and cancer. In particular, ERAP1 is a major risk gene identified in genome-wide association studies of MHC-I associated inflammatory conditions (or "MHC-I-opathies"), including Ankylosing Spondylitis, Bechet's disease, Birdshot Uveitis, and Psoriasis. In these conditions, ERAP1 is often in epistasis with the primary risk MHC-I allele. Other disease associations include insulin dependent Diabetes Mellitus and Multiple Sclerosis. Historically, ERAP1 gene associations were first reported in Hypertension. Emerging evidence links ERAP1 SNVs to cancer development, and susceptibility to infectious disease, such as ERAP1 SNVs that modify the resistance to influenza virus infection.
=== Amphetamines === Amphetamines are the largest group of stimulants. Amphetamine was first used in the 1930s as a drug to treat various medical conditions such as narcolepsy and depression. However, during World War II, amphetamine was given to soldiers to keep them awake and alert. Soon, it leads to athletes abusing it to gain an advance. Usage of stimulants, such as amphetamine, can lead to death. In 1960, Danish cyclist Kurt Enemar Jensen died from amphetamine use during the Summer Olympics, and British cyclist Tommy Simpson died during the 1967 Tour de France with alcohol and amphetamines in his system. Amphetamines manipulate the levels of certain neurotransmitters in the central nervous system (CNS) and the peripheral nervous system (PNS).
For convenience, three different views of the data are available on Wikipedia: two sets of "segmented tables", and a single "unitized table (all elements)". The unitized table allows easy visualization of proton/neutron-count trends but requires simultaneous horizontal and vertical scrolling. The segmented tables permit easier examination of a particular chemical element with much less scrolling. Links are provided to quickly jump between the different sections.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.